No Indication of Abuse or Withdrawal Potential with Esmethadone (REL-1017): Results From Two Phase 3 Randomized Placebo-Controlled Trials in Patients With Major Depressive Disorder
Authors: Pappagallo M, Shram M, Henningfield J, Gorodetsky C, De Martin S, Vocci F, Sapienza F, Kosten T, Guidetti C, O’Gorman C, Folli F, Traversa S, Inturrisi C, Manfredi P Background: Esmethadone (REL-1017) is a promising adjunctive antidepressant candidate currently in Phase 3 development as an N-methyl-D-aspartate receptor uncompetitive antagonist. It is the dextro-isomer of… Read More